Company Overview
Snapshot
Founded in January 2023, Noxon operates with 1–10 employees. The company has secured funding across one round from one investor, NGT HealthCare II, to advance its drug development for fibrotic lung diseases.
Business overview
Noxon is a Health Tech & Life Sciences company focused on developing novel oral treatments for fibrotic lung diseases. Its core product, 3-CP (3-cabamoyl-proxyl), is a stable organic radical from the nitroxides group with unique antioxidant properties. This drug has demonstrated efficacy in reducing airway inflammation and hyper-responsiveness in animal models of allergic asthma, targeting the pharmaceutical and healthcare markets.
Log in to access full profile ›Company Intelligence Q&A
- What is Noxon's primary focus?
- Noxon is dedicated to the development of a novel drug for the oral treatment of fibrotic lung diseases.
- What is the key product developed by Noxon?
- Noxon's key product is 3-CP (3-cabamoyl-proxyl), a stable organic radical belonging to the nitroxides group, which possesses unique antioxidant properties.
- What therapeutic effects has 3-CP demonstrated?
- In animal models of allergic asthma, 3-CP has been shown to reduce airway inflammation, airway hyper-responsiveness, and other inflammatory mediators in lung tissues.
- When was Noxon founded?
- Noxon was founded in January 2023.